Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

  • Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • A Coruña
  • Barcelona
  • Bristol
  • Cagliari
  • Cambridge
  • Clermont-Ferrand
  • Corbeil-Essonnes
  • Dresden
  • Exeter
  • Ferrara
  • Firenze
  • Frankfurt am Main
  • Freiburg im Breisgau
  • Gommern
  • Granada
  • Halle (Saale)
  • Heidelberg
  • L'Hospitalet de Llobregat
  • Le Mans
  • Lille
  • Lübeck
  • Madrid
  • Mainz
  • Milano
  • Montpellier
  • Málaga
  • Nantes
  • Paris
  • Pessac
  • Pisa
  • Plymouth
  • Ratingen
  • Roma
  • Sabadell
  • Saint-Étienne
  • Salford
  • Sevilla
  • Siena
  • Torino
  • Torquay
  • Toulouse
  • Truro
  • Valladolid
  • Vigo
  • westcliff-on-sea
  • Wolverhampton
Trial Identifier:

NCT02654379 BA28478

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT02654379, BA28478 Trial Identifier
      Rituximab Treatments
      Off-Label Use Condition
      Official Title

      MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Participant is in the center to receive an infusion for rituximab for a non-oncology indication during the study period
      • Aged 18 years or older
      Exclusion Criteria
      • Has previously already completed the rituximab survey
      • Has participated in the past 12 months in a clinical trial in which rituximab was one of the treatments being evaluated.

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Cancer

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now